Amneal Pharmaceuticals (AMRX) Payables (2017 - 2026)

Amneal Pharmaceuticals has reported Payables for 10 years, with the latest figure at $721.2 million in Q2 2026.

• On a quarterly basis, Payables rose 8.16% year-over-year to $721.2 million in Q2 2026; TTM through Jun 2026 was $721.2 million, a 8.16% increase from a year earlier, with the FY2025 full-year figure at $761.3 million, up 3.52% from the prior year.
• Payables was $721.2 million for Q2 2026 at Amneal Pharmaceuticals, up from $663.0 million in the prior quarter.
• The five-year high for Payables was $761.3 million in Q4 2025, with the low at $482.2 million in Q1 2023.
• Average Payables over 5 years is $616.3 million, with a median of $607.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2024: Payables decreased 13.92% in 2022, then jumped 37.55% in 2024.
• Over 5 years, Payables stood at $540.7 million in 2022, then slipped by 1.11% to $534.7 million in 2023, then surged by 37.55% to $735.4 million in 2024, then advanced by 3.52% to $761.3 million in 2025, then decreased by 5.27% to $721.2 million in 2026.
• The last three Payables figures came in at $721.2 million (Q2 2026), $663.0 million (Q1 2026), and $761.3 million (Q4 2025), per Business Quant data.